Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Copenhagen OE, Denmark Clinical Trials

A listing of Copenhagen OE, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

The purpose of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).

Phase

0.0 miles

Learn More »

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042 an Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion. The cohort expansion may include various tumor ...

Phase

0.0 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

1.41 miles

Learn More »

Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth

Hyposalivation and xerostomia are the most common long-term side effects to radiotherapy of head and neck cancers. A randomized clinical trial indicates that autologeous mesenchymal stem/stromal cells can restore function of the submandibular glands. Patients with previous oropharynx cancer and radiation-induced hyposalivation and xerostomia will be treated with culture expanded ...

Phase

2.01 miles

Learn More »

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.

Phase

2.25 miles

Learn More »

Study Of Vinblastine in Combination With Nilotinib in Children Adolescents and Young Adults

Low grade gliomas (LGG) are the most frequent brain tumor type in children. They are often chemosensitive. However, more than 50% of these tumors will progress within the first 5 years after the start of the treatment and need a second-line therapy (Laithier, JCO 2003). In most cases, patients are ...

Phase

2.25 miles

Learn More »

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).  

Phase

2.25 miles

Learn More »

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).

Phase

2.25 miles

Learn More »

Study Assessing the Safety Tolerability Pharmacokinetics Food Effect and Drug-Drug Interactions of PTI-801 in Healthy Volunteers and Safety Tolerability and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. Following the conclusion of at least three SAD cohorts, a set of HV will participate in an assigned MAD treatment group. The MAD treatment group is comprised of three ...

Phase

2.25 miles

Learn More »

Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Phase

2.25 miles

Learn More »